NINJ1 targeting shows promise for multiple sclerosis and other brain injuries

People with multiple sclerosis, ischemic stroke, traumatic brain injury, spinal cord injury, neuropsychiatric disorders, and neurodegenerative diseases face difficult challenges. A new narrative review looks at a specific target called NINJ1. This target is found in cells throughout the body. Scientists are exploring ways to use monoclonal antibodies, functional peptides, or small-molecule inhibitors to block or change how NINJ1 works. The goal is to protect brain cells and improve recovery. This review gathered information about these different approaches. It did not test a specific drug on patients. Instead, it looked at what is already known about NINJ1 in the central nervous system. The central nervous system includes the brain and spinal cord. The review found that we do not yet know the precise role of NINJ1 in this system. There are also critical knowledge gaps regarding how NINJ1 functions in different cell types. Because of these gaps, the review could not confirm if blocking NINJ1 would be safe or effective. No safety data or specific results were reported because this was a review of existing ideas. The authors note that more research is required before anyone can recommend this approach. Until then, these methods remain theoretical targets for future study.